LLY Shares Outstanding
Total shares outstanding each quarter, showing dilution from issuance or reduction from buybacks.
Shares Outstanding
Latest: 941M (2026Q2)
| Period | Value |
|---|---|
| 2020Q3 | 911M |
| 2020Q4 | 957M |
| 2021Q1 | 912M |
| 2021Q2 | 910M |
| 2021Q3 | 911M |
| 2021Q4 | 957M |
| 2022Q1 | 906M |
| 2022Q2 | 903M |
| 2022Q3 | 904M |
| 2022Q4 | 950M |
| 2023Q1 | 903M |
| 2023Q2 | 903M |
| 2023Q3 | 900M |
| 2023Q4 | 949M |
| 2024Q1 | 904M |
| 2024Q2 | 904M |
| 2024Q3 | 905M |
| 2024Q4 | 949M |
| 2025Q1 | 901M |
| 2025Q2 | 900M |
| 2025Q3 | 899M |
| 2025Q4 | 945M |
| 2026Q1 | 896M |
| 2026Q2 | 941M |
* In some reporting periods, diluted weighted-average shares are used instead of period-end shares outstanding. Please verify individual figures against the company's SEC filings.
Other LLY Charts
More quarter-by-quarter fundamentals for Eli Lilly and Company
1 / 10
Revenue
EPS
Free Cash Flow
Gross Margin
FCF Margin
P/E Ratio
Cumulative FCF
Total Assets
Total Debt
Rule of 40
Healthcare Comparison
1 / 3
Shares Outstanding
Shares Outstanding
Shares Outstanding
Latest Shares Outstanding: 941M (2026Q2); +4.6% YoY; −1.2% CAGR since 2009Q2 (17y).
Across the 62 quarters from 2009Q2 to 2026Q2, Shares Outstanding ranged from 896M in 2026Q1 to 1.16B in 2012Q4.
Chart and table show the latest 24 of 62 quarters.